The number of pages within the document is: 13
The self-declared author(s) is/are:
Mohd Zaki
The subject is as follows:
Original authors did not specify.
The original URL is: LINK
The access date was:
2019-01-23 11:59:12.175643
Please be aware that this may be under copyright restrictions. Please send an email to admin@pharmacoengineering.com for any AI-generated issues.
Loading...
Reload document 
Open in new tab The content is as follows:
International Journal of PharmTech Research CODEN (USA): IJPRIF ISSN : 0974-4304 Vol.4, No.1, pp 280-292, Jan-Mar 2012 Implantable Drug Delivery System: A Review Mohammad Zaki AJ. 1*, Satish K. Patil 1, Dheeraj T. Baviskar 1,Dinesh K. Jain 21Department of Pharmaceutics, Institute of Pharmaceutical Education, Boradi, Shirpur, Dhule (MS) Π425428, India. 2Department of Pharmaceutics, College of Pharmacy, IPS Academy, Indore Р452 012, (MP)India. *Corres. Author: zaki847@gmail.com Mobile. No: +919890143220, +918275233660 Abstract: In the past, drugs were frequently administered orally, as liquids or in powder forms. To avoid problems incurred through the utilization of the oral route of drug administration, new dosage forms containing the drug(s) were introduced. As time progressed, there was a need for delivery systems that could maintain a steady release of drug to the specific site of action. Therefore, drug delivery systems were developed to optimize the therapeutic properties of drug products and render them more safe, effective, and reliable. Implantable drug delivery systems (IDDS) are an example of such systems available for therapeutic use. The study of currently available implantable drug delivery systems is the main focus of this review. The major advantages of these systems contain targeted local delivery of drugs at a constant rate, fewer drugs required to treat the disease state, minimization of probable side effects, and better efficacy of treatment. Due to the development of such sustained release formulations, it is now possible to administer unstable drugs once a week to once a year that in the past required frequent daily dosing. Preliminary studies using these systems have shown superior effectiveness over conventional methods of treatment. However, one limitation of these newly developed drug delivery systems is the fact that their cost-to- benefit ratio (cost/benefit) is too high which restricts their use over conventional dosage forms. Some of the most recently discovered implants are in the early developmental stages and more rigorous clinical testing is required prior to their use in standard practice. Keywords: Implantable drug delivery, modulated drug delivery, implants, drug delivery systems, implantable pumps, recent technologies. 1. INTRODUCTION Orally administered drug must be protected against denaturation in the gastrointestinal tract and should be capable of absorption across the wall of the stomach or the intestine. After absorption and upon reaching the portal circulation, it must be resistant to hepatic enzymes. The rate of drug absorption and elimination should ensure the blood levels within the therapeutic range. Moreover, the amount of intact drug that reaches the site of action should be sufficiently large to obtain desired therapeutic effect but insufficient to cause untoward side effects.A controlled drug action may be achieved by either chemically modifying the drug moiety or by formulating it in a specific way to control its release. Oral controlled release dosage forms can provide efficacy for about 24 hours. The main drawback of oral dosage form is the long transit time of approximately 12hours through the gastrointestinal tract (GIT). If drug cannot be administered orally, a parenteral route of delivery is an alternative. Many proteins/peptides and other drugs, which are susceptible to the adverse conditions of GIT, are
Please note all content on this page was automatically generated via our AI-based algorithm. Please let us know if you find any errors.